They describe the Sisterhood's modest beginnings, its impact already, and plans for the future. It now has a 501c3 charity structure and more formal leadership, and there are new efforts to reach other c-suite level women in biotech.

Interviewed by Sisterhood editorial board member Daphne Zohar, Kate Haviland talks about the numerous programs that Blueprint created, the rationale behind key go/no-go and partnering decisions, and how she feels about the biotech sector today. Biographies Kate Haviland was the Chief Executive Officer of Blueprint Medicines, which was acquired by Sanofi in 2025 for a total equity value, including potential CVR payments, of approximately $9.5. Previously, she served as Chief

Interviewed by Sisterhood editorial board member Erika Smith, Nina Tandon describes what it has taken to get a startup through the recent difficult times for the biotech sector, including applying for military funding and making the product available in international markets where compassionate use is an option. Biographies Dr. Nina Tandon is the CEO and Co-Founder of EpiBone, Inc., a groundbreaking biotech company revolutionizing skeletal reconstruction with AI-designed, 3D-

Interviewed by Sisterhood editorial board member Grace Colón, Dr. Gujrathi discusses a three pillar framework for success she has learned during her career in life sciences: know thyself, understand your environment, and set yourself up for success. Interview Chapters: Sheila’s background - 0:34 | Framework of success - 6:21 | Getting everyone involved - 16:51 | Not sacrificing the good for the perfect - 19:37 | A culture of accepting feedback - 23:03 | Compassion - 28:2

Interviewed by Sisterhood editorial board member Erika Smith, Reenie McCarthy discusses how working with the Barth Syndrome Community, an ultra rare disease, helped the company better understand outcomes that are important to daily life for these patients. She also highlights the role that mitochondria play in biology, and the future of treatments for diseases of mitochondrial dysfunction. Biographies Reenie McCarthy is the Chief Executive Officer, President and a member of t

She describes the process of how the company's computing platform sorts through proteins that are secreted by stem cells and screens them...

Interviewed by Sisterhood editorial board member Sheila Gujrathi, Kiran Mazumdar-Shaw describes her beginnings in designing enzymes, and...

Interviewed by Xilio Therapeutics President & CEO René Russo, Dr. Liebisch describes her start in the industry as a patent attorney,...

Interviewed by Sisterhood editorial board member Erika Smith, Jennifer Good describes the factors that have led to Trevi's success in an...

Interviewed by Sisterhood editorial board member Daphne Zohar, Sophie Kornowski shares her keys to creating great assets,...

Interviewed by Sisterhood editorial board member Grace Colón, she describes the unmet need for developing evidence based products for...

Interviewed by Sisterhood editorial board member Julia Owens, Catherine Owen Adams shares her career journey, and discusses the perceived...

Interviewed by Sisterhood editorial board member Erika Smith, Paula Ragan shares her career path and things she has learned along the...

Interviewed by Normunity CEO Rachel Humphrey at MassBio's 2025 State of Possible Conference, Luba explains how the Sisterhood arms...

Interviewed by Sisterhood editorial board member Sheila Gujrathi, Yvonne Greenstreet describes her upbringing and early career as a...

Interviewed by Sisterhood editorial board member Grace Colón, Marianne De Backer advocates for the importance of getting experience in a...

Interviewed by ReCode Therapeutics' CEO Shehnaaz Suliman, she describes the journey of co-founding companies including AskBio, Bamboo...

Interviewed by Sisterhood editorial board member Sheila Gujrathi, Sarah Boyce describes how to recognize dysfunction and the importance...

Interviewed by Sisterhood editorial board member Julia Owens, Dr. Hedley, who was the co-founder of TESARO and today is a member of...

Sisterhood editorial board members Daphne Zohar (Seaport Therapeutics) and Luba Greenwood (Gallop Oncology) share their experiences about...